西亚试剂：Immunotherapy: The Path to Win the War on Cancer?

Drugs targeting immune checkpoint molecules such as CTLA-4, PD-1, and PD-L1 are being heralded as a breakthrough in oncology. However, “breakthrough” is a misnomer belying several decades of basic immunology advances and clinical trial and error leading up to this point. It was only after basic science uncovered the protean pathways restraining anti-tumor immunity that we could begin to unravel how to subvert them. The broad activity spectrum of PD-1 pathway blockers against multiple cancer types has validated this as a “common denominator” treatment approach and dispels the perception that “immunogenic” cancers are anomalies.

以上资料由西亚试剂：http://www.xiyashiji.com/ 提供